UVA Health researchers have discovered a potential way to predict which patients with severe COVID-19 are likely to recover well and which are likely to suffer “long-haul” lung problems. That finding could help doctors better personalize treatments for individual patients.
The researchers estimated vaccine effectiveness (VE) against long COVID in children aged 5 to 17 years. Though severe COVID-19 cases are less common in children than in adults, persistent symptoms in children do occur.